Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.
Publication
, Journal Article
Dzimitrowicz, HE; Armstrong, AJ
Published in: Eur Urol
December 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
December 2022
Volume
82
Issue
6
Start / End Page
599 / 601
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Male
- Humans
- Hormones
- Androgen Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dzimitrowicz, H. E., & Armstrong, A. J. (2022). Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment. Eur Urol, 82(6), 599–601. https://doi.org/10.1016/j.eururo.2022.08.031
Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.” Eur Urol 82, no. 6 (December 2022): 599–601. https://doi.org/10.1016/j.eururo.2022.08.031.
Dzimitrowicz HE, Armstrong AJ. Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment. Eur Urol. 2022 Dec;82(6):599–601.
Dzimitrowicz, Hannah E., and Andrew J. Armstrong. “Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.” Eur Urol, vol. 82, no. 6, Dec. 2022, pp. 599–601. Pubmed, doi:10.1016/j.eururo.2022.08.031.
Dzimitrowicz HE, Armstrong AJ. Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment. Eur Urol. 2022 Dec;82(6):599–601.
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
December 2022
Volume
82
Issue
6
Start / End Page
599 / 601
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Prostatic Neoplasms
- Male
- Humans
- Hormones
- Androgen Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences